Albumin-bilirubin score is a prognostic factor in hepatocellular carcinoma treated with transarterial radioembolization: A retrospective cohort study

doi:10.4251/wjgo.120863

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 9

This Article

(9)

(11)

(0)

(117)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Oncology

ISSN

1948-5204

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastrointest Oncol. Sep 15, 2026; 18(9): 120863
Published online Sep 15, 2026. doi: 10.4251/wjgo.120863

Table 2 Tumor disease characteristics, median (interquartile range)/n (%)

Variable	Patients (n = 50)
Previous treatments	18 (36)
TACE	9 (18)
Systemic therapy	6 (12)
Thermal ablation	3 (6)
Hepatectomy	1 (2)
Unilobar hepatocellular carcinoma	38 (76)
Satellite nodules	16 (32)
Portal infiltration	4 (8)
Maximum diameter of the main lesion, cm	4.6 (3.5-6.6)
Number of HCC
1	26 (52)
2	7 (14)
3	8 (16)
More than 3	9 (18)
Tumor burden score¹	5.5 (4-7.1)
BCLC stage
A	15 (30)
B	32 (64)
C	3 (6)
AFP < 400 ng/mL, n (%)	42 (84)

¹Tumor burden score = [(maximum tumor diameter)² + (number of tumors)²]^(1/2).

TACE: Transarterial chemoembolization; HCC: Hepatocellular carcinoma; BCLC: Barcelona Clinic Liver Cancer; AFP: Alpha-fetoprotein.

Full Size Table

Citation: Suárez-Toribio Á, López-Bueno I, Ampuero-Herrojo J, Cabanillas-Casafranca M, Giráldez-Gallego Á, Sousa-Martín JM, Tirado-Hospital JL, Iglesias-López Á, Nacarino-Mejías V, Ferrer-Ríos MT. Albumin-bilirubin score is a prognostic factor in hepatocellular carcinoma treated with transarterial radioembolization: A retrospective cohort study. World J Gastrointest Oncol 2026; 18(9): 120863
URL: https://www.wjgnet.com/1948-5204/full/v18/i9/120863.htm
DOI: https://dx.doi.org/10.4251/wjgo.120863

Suárez-Toribio Á, López-Bueno I, Ampuero-Herrojo J, Cabanillas-Casafranca M, Giráldez-Gallego Á, Sousa-Martín JM, Tirado-Hospital JL, Iglesias-López Á, Nacarino-Mejías V, Ferrer-Ríos MT. Albumin-bilirubin score is a prognostic factor in hepatocellular carcinoma treated with transarterial radioembolization: A retrospective cohort study. World J Gastrointest Oncol 2026; 18(9): 120863 [DOI: 10.4251/wjgo.120863]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.